Complement System

Complement System製品

• All (17)
• Complement System阻害剤 (9)
• Complement System抗体(2)
• Complement System拮抗剤(2)
• Complement System作動薬(2)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2286	Cyclosporin A	Cyclosporin A, a non-polar cyclic oligopeptide, is an immunosuppressive agent that binds to cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay. Cyclosporin A is generally given following transplant surgery to prevent rejection and has been used to test its toxic effect on a perfused 3D proximal tubule model.	Cell Rep, 2024, S2211-1247(23)01591-7 mSphere, 2024, 9(1):e0055423 Food Chem Toxicol, 2024, 188:114665
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Cell Host Microbe, 2024, S1931-3128(24)00005-2 Nat Commun, 2024, 15(1):7991 Nat Commun, 2024, 15(1):1176
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460 iScience, 2022, 25(12):105682
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Cancer Cell, 2024, 42(9):1507-1527.e11 Pharmaceutics, 2022, 14(2)400 Front Oncol, 2022, 12:888695
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	Cell Death Dis, 2023, 14(4):285 Front Neurosci, 2022, 16:951491 Mol Pain, 2022, 18:17448069221140532
S8522	Compstatin	Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.	bioRxiv, 2023, 2023.03.30.535001 Sci Rep, 2022, 12(1):5818 Stem Cell Reports, 2021, 16(9):2305-2319
S3612	Rosmarinic acid	Rosmarinic acid (RA, Rosemary acid) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.	Free Radic Biol Med, 2021, S0891-5849(21)00198-2
S3240	Phaseoloidin	Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. Phaseoloidin has anti-complement effects.
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
A2847	Lendalizumab (Anti-Complement C5)	Lendalizumab (Anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities. MW : 146.02 KD.
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.
S0803	Danicopan	Danicopan is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
S9138	Picfeltarraenin IA	Picfeltarraenin IA is an AChE inhibitior, and an potential PI3K and EGFR inhibitor. It also acts as an inhibitor on both the classical and alternative pathways of the complement system.
A2812	Crovalimab (Anti-Complement C5)	Crovalimab (Anti-Complement C5) is a humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. MW : 145.28 KD.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
S2286	Cyclosporin A	Cyclosporin A, a non-polar cyclic oligopeptide, is an immunosuppressive agent that binds to cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay. Cyclosporin A is generally given following transplant surgery to prevent rejection and has been used to test its toxic effect on a perfused 3D proximal tubule model.	Cell Rep, 2024, S2211-1247(23)01591-7 mSphere, 2024, 9(1):e0055423 Food Chem Toxicol, 2024, 188:114665
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Cell Host Microbe, 2024, S1931-3128(24)00005-2 Nat Commun, 2024, 15(1):7991 Nat Commun, 2024, 15(1):1176
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460 iScience, 2022, 25(12):105682
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Cancer Cell, 2024, 42(9):1507-1527.e11 Pharmaceutics, 2022, 14(2)400 Front Oncol, 2022, 12:888695
S8522	Compstatin	Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.	bioRxiv, 2023, 2023.03.30.535001 Sci Rep, 2022, 12(1):5818 Stem Cell Reports, 2021, 16(9):2305-2319
S3612	Rosmarinic acid	Rosmarinic acid (RA, Rosemary acid) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.	Free Radic Biol Med, 2021, S0891-5849(21)00198-2
S3240	Phaseoloidin	Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. Phaseoloidin has anti-complement effects.
S0803	Danicopan	Danicopan is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
S9138	Picfeltarraenin IA	Picfeltarraenin IA is an AChE inhibitior, and an potential PI3K and EGFR inhibitor. It also acts as an inhibitor on both the classical and alternative pathways of the complement system.
A2847	Lendalizumab (Anti-Complement C5)	Lendalizumab (Anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities. MW : 146.02 KD.
A2812	Crovalimab (Anti-Complement C5)	Crovalimab (Anti-Complement C5) is a humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. MW : 145.28 KD.
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	Cell Death Dis, 2023, 14(4):285 Front Neurosci, 2022, 16:951491 Mol Pain, 2022, 18:17448069221140532
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.